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(CAR)-modified T cells is a promising cancer immunotherapy.
We previously developed a non-viral method of gene transfer
into T cells using a piggyBac transposon system to improve
the cost-effectiveness of CAR-T cell therapy. Here, we have
further improved our technology by a novel culture strategy
to increase the transfection efficiency and to reduce the time
of T cell manufacturing. Using a CH2CH3-free CD19-specific
CAR transposon vector and combining irradiated activated
T cells (ATCs) as feeder cells and virus-specific T cell receptor
(TCR) stimulation, we achieved 51.4% ± 14% CAR+ T cells
and 2.8-fold expansion after 14 culture days. Expanded
CD19.CAR-T cells maintained a significant fraction of
CD45RA+CCR7+ T cells and demonstrated potent antitumor
activity against CD19+ leukemic cells both in vitro and in vivo.
Therefore, piggyBac-based gene transfer may provide an alter-
native to viral gene transfer for CAR-T cell therapy.
INTRODUCTION
Adoptive immunotherapy using chimeric antigen receptors (CARs)
to target tumor-associated antigens represents a novel approach
for the treatment of hematological malignancies. In particular,
CD19.CAR-T cells promoted substantial clinical responses in the
patients with refractory or relapsed acute lymphoblastic leukemia
(ALL).1–4
CAR expression in T cells is generally obtained via gene transfer with
viral vectors. To reduce the costs of manufacturing and potentially
enhance the safety of the gene transfer procedure, we developed a
non-viral method of gene transfer in T cells using the piggyBac
transposon system.5–7 We found that the piggyBac transposon system
allows the generation of highly functional CD19.CAR-T cells.8 How-
ever, our in vitro culture procedure for expanding piggyBac-modifiedMolecular Therapy: Methods &
This is an open access article under the CC BY-NC-CD19.CAR-T cells remains suboptimal since it requires a step of mag-
netic cell isolation to enrich the T cell product in CAR+ T cells and
more than 21 days of culture to generate sufficient numbers of
T cells for clinical adoptive transfer. Furthermore, our CAR included
a long IgG1-CH2CH3 spacer that might abrogate the in vivo anti-
tumor activity.9–11
The aim of the present study was to improve the manufacturing of
piggyBac-modified CD19.CAR-T cells to achieve high levels of CAR
expression and reduce the duration of the in vitro culture.We hypoth-
esized that these goals can be obtained by (1) adding autologous
activated T cells (ATCs), which express multiple co-stimulatory
molecules, as feeder cells; (2) stimulating T cells via viral antigens
rather than mitogenic anti-CD3/CD28 monoclonal antibodies
(mAbs); and (3) using a CH2CH3-free CD19.CAR construct to
render in vivo persistence and antitumor activity.RESULTS
Feeder-Irradiated Autologous ATCs Enhance CARExpression in
piggyBac-Modified CD19.CAR-T Cells
We previously reported that feeder cells enhance the expansion rate of
piggyBac-modified T cells.5 To determine whether autologous ATCs
can improve the expansion and CAR expression of piggyBac-modified
CD19.CAR-T cells, irradiated autologous ATCs were added to the
culture on days 0 and 7 after transfection. In brief, peripheral blood
mononuclear cells (PBMCs) were transfected with CD19.CARClinical Development Vol. 8 March 2018 ª 2017 The Authors. 131
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Feeder Irradiated Autologous Activated T
Cells Enhance CAR Expression in piggyBac-
Modified CD19.CAR-T Cells
(A) Schematic explanation of the generation method of
PB-modified CD19.CAR-T cells in the original or the CD3/
CD28-ATC condition. 1 107 of PBMCswere transfected
with CD19.CAR via the piggyBac transposon system and
stimulated on a CD3/CD28 mAb-coated plate supple-
mented with IL-7 and IL-15 in the absence (original
method) or presence (CD3/CD28-ATC method) of autol-
ogous activated T cells (ATCs) as feeder cells. In the CD3/
CD28-ATC method, irradiated autologous ATCs were
added on day 0 and day 7 following nucleofection. Four-
teen days after nucleofection, cells were harvested and
analyzed. (B) Ex vivo expansion of PB-modified
CD19.CAR-T cells. Cell numbers were determined via a
trypan blue exclusion assay on days 7 and 14. Data are
presented as the mean ± SD of experiments from nine
donors. (C and D) CD19.CAR expression on PB-modified
T cells was examined via flow cytometry with the use of a
specific anti-idiotype scFv mAbs. Representative (C) and
summary (D) results from nine donors are shown. (E)
Absolute CAR+ T cell numbers were calculated based on
the total cell numbers and CAR+CD3+ percentages by
flow cytometry. The data are presented as the mean ± SD
from nine donors.
Molecular Therapy: Methods & Clinical Developmentencoding PB transposon and stimulated on anti-CD3/CD28 mAb-
coated plates supplemented with interleukin (IL)-7 (10 ng/mL) and
IL-15 (5 ng/mL), in the presence (CD3/CD28-ATC method) or
absence (original method) of autologous ATCs (Figure 1A). While
T cell proliferation was comparable in the two culture conditions
(Figure 1B), T cells generated with feeder ATCs (CD3/CD28-ATC)
exhibited significantly higher levels of CAR expression (10.7% ±
7.8%) compared to those with no feeder ATCs (original) (4.6% ±
3.2%) (p = 0.029) (Figures 1C and 1D). As a consequence, the absolute
number of CAR+ T cells at the end of the culture expansion increased
from 2.6 ± 2.2  106 cells (original method) to 7.6 ± 8.0  106 cells
(CD3/CD28-ATC) (p = 0.049) (Figure 1E). These results suggest
that irradiated ATCs helps in increasing the frequency of CAR-
expressing T cells.
Although higher numbers of CAR+ T cells were obtained using feeder
ATCs, their frequencies remain suboptimal for the clinical applica-
tion. These results prompted us to further improve our method of
CAR-T cell generation.
Virus-Specific TCR Stimulation Increases CAR Expression in
piggyBac-Modified CD19.CAR-T Cells
To determine whether physiological T cell receptor (TCR) stimula-
tion enhances CAR expression and expansion of piggyBac-modified
CD19.CAR-T cells, we used a mix of four common viral antigens
(ACE; AdV5 Hexon, CMV pp65, EBV EBNA-1, and BZLF1) for
the stimulation of T cells. In brief, piggyBac-modified CD19.CAR-T
cells were stimulated twice by either irradiated ATCs pulsed with
ACE viral peptides (ACE CAR) or ATCs and anti-CD3/CD28132 Molecular Therapy: Methods & Clinical Development Vol. 8 MarchmAbs (CD3/CD28-ATC CAR) (Figure 2A). T cell expansion rates
were comparable for 14 days of culture (Figure 2B). In contrast,
ACE CAR-T cells exhibited significantly higher (33.0% ± 9.7%)
CAR expression than the CD3/CD28-ATC CAR-T cells (10.7% ±
7.8%; p = 0.001) (Figures 2C and 2D). Furthermore, the mean fluores-
cence intensity of the CAR expression was significantly higher in ACE
CAR-T cells than those of both original and CD3/CD28-ATC CAR-T
cells (Figures S1 and S2). As a consequence, ACE CAR-T cells showed
higher absolute numbers of CAR+ T cells (17.2 106) at the end of the
culture period as compared to CD3/CD28-ATC CAR method (7.6 
106; p = 0.047) (Figure 2E). CAR+ T cell numbers in the ACE CAR-T
group were 6.6-fold higher (p = 0.028) than those generated using the
original method (2.6 ± 2.2  106) (Figures 1E and 2E).
We assessed the secretion of interferon (IFN)-g in response to the
four common viral antigens (ACE; AdV5 Hexon, CMV pp65, EBV
EBNA-1, and BZLF1) using the enzyme-linked immunosorbent
spot (ELISpot) assay to determine the virus-specific activity of the
generated CAR-T cells. Unexpectedly, IFN-g secretion minimally
increased in response to viral antigens by ACE CAR-T cells relative
to the background IFN-g secretion in the negative control (Figure S3).
To determine whether the presence of CAR in T cells attenuated the
virus-specific activity, we separately evaluated the virus-specific activ-
ity by intracellular cytokine assay in both CAR and NT population of
ACE CAR-T cells from donor 1, which demonstrated apparent virus
specificity on day 14. Although IFN-g in response to pp65 antigen
was detected in the CAR population, it was minimally detected in
the CAR+ population (Figure S4). To confirm this, we compared2018
Figure 2. Viral Antigen Stimulation Significantly Increases CAR Expression in PB-Modified CD19-Specific T Cells
(A) Schematic explanation of the generationmethod of PB-modified CD19.CAR-T cells in the CD3/CD28-ATC or the ACE condition. 1 107 of PBMCs were transfected with
CD19.CAR via the piggyBac transposon system and stimulated with either irradiated autologous ATCs and CD3/CD28 mAbs (CD3/CD28-ATC CAR method) or irradiated
autologous ATCs pulsed with viral peptides (ACECARmethod) on days 0 and 7 after nucleofection. The cells were harvested and analyzed on day 14. (B) Ex vivo expansion of
PB-modified CD19.CAR-T cells. Cell numbers were determined by a trypan blue exclusion assay on days 7 and 14. Data are presented as themean ±SD of experiments from
nine donors. (C and D) CD19.CAR expression on PB-modified T cells was examined by flow cytometry. Representative (C) and summary (D) results from nine donors are
shown. The results are presented as themean ± SD. (E) CAR+ T cell numbers are calculated based on the total cell numbers and CD3+ CAR+ percentages determined by flow
cytometry. Data are presented as the mean ± SD from nine donors.
www.moleculartherapy.orgthe virus specificity between CAR-transduced and non-transduced
(NT) T cells, both stimulated by autologous ATCs and ACE viral pep-
tides. As compared to ACE CAR-T cells, ACE NT-T cells demon-
strated a tendency of increased virus-specific activities against viral
antigens (Figure S5). Furthermore, sequential ELISpot assays showed
that ACE CAR-T cells seem to maintain the virus specificity by day 7
but lose their specificity by day 14 as compared to ACE NT-T cells
(Figure S6). These results suggested that the presence of CAR might
be one of the reasons for the attenuated virus-specific activity in ACE
CAR-T cells after the second stimulation of ACE peptides.
To characterize the immunophenotypic composition of the T cell
products, the cells were harvested and analyzed by flow cytometry
by day 14 after transfection. As shown in Figure 3A, ACEMoleculCD19.CAR-T cells consisted of 94.2% ± 3.7% CD3+ T cells with a
higher percentage of CD8+ (79.9% ± 5.9%) than CD4+ (29.6% ±
17.3%) T cells. CD56+CD3 NK cells account for 1.6% ± 1.0%
of the total cells as previously described.8 Furthermore, ACE
CD19.CAR-T cells contained 79.9% ± 5.9% cells which co-expressed
CD45RA and CCR7 (Figures 3B and 3C) that resemble naive or stem
cell memory-like T cell phenotype.8 In contrast, ACE NT-T cells
exhibited more differentiated phenotype (Figure S7), consistent
with their virus-specific activity.
To investigate whether virus-specific TCR stimulation reduces the rate
of activation-induced cell death as compared to anti-CD3/CD28
mAb stimulation, 7 days after stimulation, the frequency of apoptotic
cells was evaluated by flow cytometry. As shown in Figure S8, ACEar Therapy: Methods & Clinical Development Vol. 8 March 2018 133
Figure 3. The Major Subset of ACE CAR-T Cells Was Phenotypically CD8+CD45RA+CCR7+, Closely Related to T-Memory Stem Cells
The phenotypical analysis of ACE CAR-T cells was performed on day 14 after nucleofection. (A) Mean percentages of CD3+CD56, CD56+CD3, CD4+CD8, and
CD8+CD4 are shown. Data are represented as the mean ± SD from nine donors. (B) Mean percentages of CD45RA+CCR7+, CD45RA+CD62L+, CD45RACCR7,
CD45RO+CD62L+, and CD45RO+CD62L are shown. Data are represented as the mean ± SD from nine donors. (C) Isotype control, CD45RA/CD62L, CD45RA/CCR7, and
CD45RO/CD62L expressions in ACE CAR-T cells. Representative results from three donors are shown.
Molecular Therapy: Methods & Clinical DevelopmentCD19.CAR-T cells showed a trend for a lower frequency of Annexin
V+ cells within the CAR+ T cells as compared to CD19.CAR-T cells
stimulated with anti-CD3/CD28 mAbs. These results suggest that
anti-CD3/CD28 mAb TCR stimulation may induce more apoptosis
in T cells leading to an overall lower output of CAR+ T cells.
ACE CD19.CAR-T Cells Exert an Anti-leukemic Effect In Vitro
To evaluate the anti-leukemic effects of ACE CD19.CAR-T cells
in vitro, we co-cultured ACE CAR-T cells with SU/SR, tyrosine kinase
inhibitors-resistant CD19+ ALL cell line.8,12 As shown in Figures 4A
and 4B, ACE CD19.CAR-T cells showed significantly higher elimina-
tion of SU/SR cells (94.7% and 87.8%) compared to both CD3/CD28-
ATC CAR-T (59.6% and 48.7%) and original CAR-T cells (51% and
34.4%) at the effector:target (E:T) ratios of 1:50 and 1:100, respec-
tively. These results suggest that ACE CD19.CAR-T cells have potent
anti-leukemic effect in vitro.
ACE CD19.CAR-T Cells with a New Transposon Vector with No
CH2CH3 Hinge Region Show Higher CAR Expression
Recently, several groups have suggested that the long CH2CH3 hinge
region may attenuate in vitro lysis of tumor cells9 or induce killing of
monocytes10 and in vivo expansion ofCAR-T cells.11 Toprovide better134 Molecular Therapy: Methods & Clinical Development Vol. 8 Marchin vivo persistence and antitumor activity, we constructed a new trans-
poson vector (CH2CH3-free) by removing the spacer region from the
original CD19.CARvector (original) based on the construct developed
byKochenderfer et al.13 (GenBank: HM852952.1). Therefore, this new
vector is 645 bp shorter than the original vector as a result of the dele-
tion (Figure 5A).We then generatedACECAR-T cells using either the
original or theCH2CH3-free vector (Figure 5A). Overall, T cell expan-
sion was similar (Figure 5B), but the CH2CH3-free construct led to
significantly higher CAR expression (51.4% ± 14%) compared to the
original construct (33.0% ± 9.7%) (p = 0.034) (Figures 5C and 5D)
and a trend of an increase in the absolute number of CAR+ T cells
(27.8 ± 28.0  106 versus 17.2 ± 17.0  106) (p = 0.23) (Figure 5E).
Similar to the results from the original vector, ACE CAR-T cells
with CH2CH3-free transposon vector contained a significant fraction
of CD3+CD45RA+CCR7+ T cells (Figure S9).
Although we compared the frequency of apoptotic cells between two
CD19.CAR vectors 7 days after stimulation to investigate whether
ACE CAR-T cells with CH2CH3-free construct reduced induced
apoptotic cell death, no differences were observed in the frequencies
of apoptotic cells between the two ACE CAR-T cell lines with either
original vector or CH2CH3-free vector (data not shown).2018
Figure 4. ACE CD19.CAR-T Cells Exhibited Potent Antitumor Activity against CD19+ Tumors, Even at a Very Low E:T Ratio
CD19.CAR-T cells generated by the original, CD3/CD28-ATC, or ACE CAR methods were co-cultured with CD19+ tumor cells (SU/SR) at effector:target (E:T) ratios of 1:5,
1:50, and 1:100 without cytokines for 5 days. The number of viable cells was determined using a trypan blue exclusion test, and the percentages of T cells and CD19+ cells
were determined by flow cytometry. (A) Representative flow cytometry results on day 5 after co-culture are shown. (B) Inhibition ratio were calculated by dividing the input
CD19+ cell number by the CD19+ cell numbers in tumor only condition. Data are presented as the mean ± SD of experiments from nine donors. *p < 0.05; **p < 0.01.
www.moleculartherapy.orgIn addition, we co-cultured CD19+ leukemic cells and analyzed them
using flow cytometry to evaluate the in vitro antitumor activity
of CH2CH3-free ACE CAR-T cells. Figure S10 shows that ACE
CAR-T cells with CH2CH3-free vector demonstrated a comparable
antitumor activity (Figure S10A) and IFN-g secretion (Figure S10B)
against SU/SR cells. These results suggested an equivalent in vitro
antitumor activity of CH2CH3-free ACE CAR-T cells as compared
to those with original vector.
ACE CD19.CAR-T Cells Exhibit an Antitumor Effect In Vivo
To evaluate the antitumor activity of ACE CD19 CAR-T cells in vivo,
we intravenously engrafted firefly luciferase (ffLuc)-labeled CD19+
Daudi cells in NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice and
subsequently infuse them with either control NT T cells or ACE
CH2CH3-free CD19.CAR-T cells 3 days following tumor inoculation
(Figure 6A). Mice treated with ACE CD19.CAR-T cells showed signif-
icantly lower tumor luminescence on days 7, 11, and 18 after tumor
inoculation as compared to themice in the controlT cell group (Figures
6B and 6C). The lower tumor luminescence in mice treated with ACE
CD19.CAR-T cells was associated with an improved overall survival
rate (p < 0.001) (Figure 6D). These results suggest that ACE
CD19.CAR-Tcells can control the growthofCD19+ tumor cells in vivo.
DISCUSSION
In the present study, we developed a novel method of piggyBac
transposon-based generation of CAR-T cells that has high potential
for the clinical translation since it achieves high expression of the
CAR in T cells and adequate expansion of T cells that retain memory
phenotype.MoleculNon-viral gene transfer methodologies, including piggyBac trans-
poson, are usually characterized by low transfection efficiency, thus
requiring magnetic purification of CAR+ cells and long-term
ex vivo culture for generating CAR-T cells for clinical use.8 In this
study, by adding ATCs as a feeder and using alternative means of
TCR stimulation using viral antigens, more than 30% of the expanded
T cells expressed the CAR. In addition, CAR expression significantly
increased to approximately 50% by just reducing the size of the CAR
cassette, eliminating the long IgG1.CH2CH3 spacer. Our experiments
also indicate that 27.8 ± 28.0  106 CAR+ T cells can be expanded
starting from 10 106 PBMCs in 14 days of culture. As several studies
have shown that of 1  3  106/kg CD19. CAR+ T cells can induce
clinical responses,4,14,15 our proposed strategy seems sufficiently
scalable to produce CAR-T cell products for clinical use.
PB-mediated gene transfer requires electroporation, which may cause
cell death. Therefore, the maintenance of an appropriate cell density is
required for the generation of PB-modified T cells.5 Several approaches
can be used to provide feeder cells to PB-modified T cells that include
engineered tumor cell lines such as K562 expressing co-stimulatory
molecules or total unfractionated PBMCs.5 However, including tumor
cell lines in culture might lead to a more complicated approval process
for clinical trials to fulfill the regulations in our country. Furthermore,
obtaining sufficient number of PBMCs is relatively challenging as
compared to the activated ATCs, which can easily be expanded, while
PBMCs are a solid option for feeder cells or simulant for T cells. Thus,
in addition to that and ATCs reportedly expressing adequate levels of
HLA class I, II, and co-stimulatory molecules,16 we selected ATCs as a
feeder cell and simulator for CAR-T cells in this study.ar Therapy: Methods & Clinical Development Vol. 8 March 2018 135
Figure 5. The Use of a New Transposon Vector without CH2CH3 Further Enhances the CAR Expression in PB-Modified T Cells
(A) Schematic representation of the transposon plasmid encoding CD19.CAR (pIRII-CAR.CD19-28-z) with (original vector) or without (short vector) IgG-CH2CH3 hinge
region. The size of the CD19.CAR plasmid was reduced from 6,438 bp to 5,798 bp by depleting the IgG1-CH2CH3 spacer. Plasmid and insert sizes of each vector are also
shown. (B) Ex vivo expansion of ACE CAR-T with the original or the short transposon vector. PBMCs were transfected with either the original or the short transposon vector
encoding CD19.CAR and cultured using the ACE CAR-T method. Cell numbers were determined by a trypan blue exclusion assay on days 7 and 14. The data are presented
as the mean ± SD of experiments from nine donors. (C and D) CD19.CAR expression on PB-modified T cells was examined by flow cytometry. Representative results (C) and
summary results (D) from nine donors are shown.
Molecular Therapy: Methods & Clinical DevelopmentThe final output of T cells activated and expanded ex vivo is the result
of a balance between T cell expansion and T cell death. In the present
study, we found that, upon CAR piggyBac gene transfer, T cell stim-
ulation obtained via TCR engagement with viral peptides had less
induced activation and cell death, which ultimately led to a significant
increase in CAR-T cell counts rather than cross-linking with mAbs.
Anti-CD3/CD28 mAb stimulation has been successfully used to
generate and expand CAR-T cells for clinical use14,15,17,18 using either
retroviral or lentiviral vectors to insert the CAR into T cells. A critical
step in the procedure of non-viral gene transfer is represented by the
electroporation of T cells. Although we do not have a mechanistic
explanation, our data suggest that the methodology used to engage
the TCR may affect the outcome of electroporated T cells causing
more death when antibodies are cross-linking TCR molecules. By
contrast, TCR engagement with peptide presented in the context of
the major histocompatibility complex (MHC) by ATCs may preserve
the physiology of electroporated cells.
Unexpectedly, ACE CAR-T cells did not secrete IFN-g against viral
peptides, although they were simulated by viral antigens during the136 Molecular Therapy: Methods & Clinical Development Vol. 8 Marchculture. Recently, Ghosh et al.19 elucidated the mechanism whereby
allogeneic CD19-targeted CAR-T cells provided anti-lymphoma
activity without causing an increased incidence of graft-versus-
host-disease in the past clinical trials. In their study, alloreactive
T cells expressing CD19.CAR with CD28 co-stimulatory domains
experienced enhanced stimulation, leading to the progressive loss of
their alloreactive effector function. In our study, although ACE
CAR-T cells seemed to maintain the virus specificity by day 7, they
lost it by day 14. In addition, the virus-specific population seemed
to be limited in the CAR population and ACE NT-T cells main-
tained the virus specificity on day 14. Together with the naive or
stem-cell memory-like phenotype in ACE CAR-T cells, one possible
explanation for this is that virus-specific TCR stimulation might have
enhanced the expansion of CAR and virus-specific TCR dual-positive
T cells and simultaneously downregulated their virus-specific TCR
after the second stimulation of ACE peptides. Further studies are war-
ranted to investigate the precise mechanism.
Cytokines’ use to expand CAR-T cells seems also important in deter-
mining not only the expansion rate of these cells but also their2018
Figure 6. ACE CD19.CAR-T Cells Potently Reject
CD19+ Leukemic Cells in a Mouse Xenograft Model
(A) NSG mice received intravenous injections (i.v.) of
1  106 Daudi cells co-expressing eGFP and ffLuc and
were subsequently intravenously infused with 1  107
CD19.CAR-T cells 3 days after tumor cell injection. Con-
trol mice were intravenously infused with 1  107 non-
transduced T cells. (B) Representative bioluminescent
imaging (BLI) of tumor progression following the i.v.
administration of tumor cells with either non-transduced
or ACE CD19.CAR-T cells are shown. (C) The mean
radiance of tumor progression imaged with BLI in mice
bearing Daudi cells is shown. **p < 0.01; ***p < 0.001.
(D) Kaplan-Meier survival curves present the overall sur-
vival. Significance was determined using a log-rank test.
www.moleculartherapy.orgimmunologic composition. By using the combination of IL-7 and IL-
15, 94% of the ex vivo expanded ACE CAR-T cells expressed CD3 and
contained both CD4+ and CD8+ T cells, with a slightly higher
percentage of CD8+. Moreover, most CAR+ T cells exhibited a
CD45RA+CCR7+ or a CD45RA+CD62L+ phenotype in our final
product, suggesting that most ACE CAR+ T cells exhibit a naive
(Tn) or stem-cell memory (Tscm) T cell phenotype
20,21 that are consid-
ered favorable phenotypic characteristics to ensure persistence and
antitumor effects upon infusion into patients, as demonstrated by
the potent anti-leukemia effects of ACE CAR-T cells in our experi-
ments in vitro and in vivo. Recently Barnett et al.22 compared the
phenotype of CAR-T cells transduced by either lentivirus or PB trans-
poson and revealed that the majority of PB-modified CAR-T cells
showed CD45RA+CD62L+, similar to our results. In contrast, lenti-
virus-transduced CAR-T cells did not show an augmented memory
phenotype. Although the precise mechanism is still unclear, PB
gene transfer system may induce expansion of CAR-T cells with
Tn/Tscm phenotype.
Although our novel method significantly improved the efficiency of
CAR-T cell generation, the efficiency was still low as compared to
another report of CAR-T cells generated by the non-viral gene trans-
fer system such as Sleeping beauty23,24 and piggyBac25 transposon.
Perhaps this could be attributed to the electroporation condition of
piggyBac-modified CAR-T cells. Recently, Ramanayake et al.25 rigor-
ously optimized their electroporation condition and determined that
the optimal voltage setting (2400 V) provided a 1.71-fold increase of
their CAR-T generation efficiency. Although our electroporation
method (4D-Nucleofector device) has a limited option of electropora-
tion conditions as compared to those (Neon Transfection System)Molecular Therapy: Methods &presented,25 the efficiency of CAR-T generation
could be potentially improved by further opti-
mization of the electroporation condition in
piggyBac-modified CAR-T cells.
Another reason could be the differences in the
culture strategy between others and ours
regarding the numbers of stimulation and thepresence of stimulation through the CAR. We stimulated T cells
only two times to reduce the culture period and avoid T cell differen-
tiation and exhaustion. Moreover, we used autologous ATCs for the
stimulation of CAR-T cells, which may minimally stimulate T cells
through the CAR because ATCs included minimal CD19+ cells as
compared to PBMCs. In contrast, Ramanayake et al.25 stimulated
their piggyBac-modified CAR-T cells three times with PBMCs. In
their method, CD19.CAR-T cells could be stimulated through the
CAR owing to the CD19+ population in PBMCs, and they achieved
765-fold expansion and 72% of the CAR expression in their
CD19.CAR-T cells. Similarly, Kebriaei et al.23 generated Sleeping
beauty-modified CAR-T cells by stimulating with CD19 and co-stim-
ulatory molecules expressing K562 cells. Although most of their
CAR+ T cells exhibited a differentiated effector memory phenotype
and an increased expression of LAG3, PDCD1LG2, and E2F
mRNA15 related to exhaustion, they achieved high CAR expression
(84%) and fold expansion (2,200–2,500) for 4 weeks of culture and
presented promising results from their clinical trials.23,24 Even though
the culture strategies and efficiencies of CAR-T cell generation were
different, these findings supported that a non-viral gene transfer sys-
tem could be an alternative option for generating CAR-T cells for
clinical use.
In conclusion, we developed a novel method of generating PB-modi-
fied CD19.CAR-T cells using minimal manipulation and reagents
that are good manufacture compliant for clinical application.
Together with the simple manufacturing process and cost-effective-
ness of DNA transposon technology, piggyBac-based gene transfer
provides an alternative to retroviral or lentiviral gene transfer for
CAR-T cell therapy. Based on these encouraging data, we currentlyClinical Development Vol. 8 March 2018 137
Molecular Therapy: Methods & Clinical Developmentplanning to conduct a clinical trial of PB-modified CD19.CAR-T cells
using our ACE CAR-T method.MATERIALS AND METHODS
Plasmids
The piggyBac transposase plasmid (pCMV-piggyBac) and transposon
plasmid for CD19.CAR (pIRII-CAR.CD19-28-z, 6,438 bp) have been
described previously.5–8 In brief, pIRII-CAR.CD19-28-z encodes a
single-chain variable fragment from the CD19 antibody (FMC63)
linked to the hinge CH2CH3 domain of human IgG1, the endodo-
mains of a CD28 molecule, and a TCR z chain. Both vectors are tran-
scriptionally regulated by the cytomegalovirus (CMV) immediate
early gene enhancer/promoter sequence. To provide better in vivo
persistence and antitumor activity, we constructed a new transposon
vector (short) that does not have the IgG1-CH2CH3 spacer region
based on the construct reported by Kochenderfer et al.13 (GenBank:
HM852952.1).Cell Lines
SU/SR were derived from SU-Ph2 by culture with imatinib as
described previously12 and maintained in RPMI 1640 medium,
supplemented with GlutaMAX and 10% fetal bovine serum
(Hyclone, Laboratories, Logan, USA). No cytokines were fed to
the co-culture.Gene Transfer into T Cells and Expansion of Transgenic T Cells
PBMCs were freshly isolated from peripheral blood of healthy do-
nors and then immediately transfected after the isolation. Healthy
volunteers gave written informed consent according to protocols
approved by the institutional review board of Shinshu University
School of Medicine, and all experiments involving human partici-
pants were performed in accordance with the guidelines established
by the Declaration of Helsinki. A 4D-Nucleofector device (Program
EO-115) and P3 Primary Cell 4D-Nucleofector X Kit (Lonza, Basel,
Switzerland) were used to electroporate 1  107 PBMCs with a
pIRII-CD19.CD28.zCAR transposon plasmid with or without the
IgG1-CH2CH3 spacer (5 mg) and a pCMV-piggyBac transposase
plasmid (5 mg) according to the manufacturer’s instructions. All cells
were cultured in animal-derived component-free T cell culture
medium (TexMACS Medium; Miltenyi Biotec, Auburn, CA, USA)
containing IL-7 (10 ng/mL, Miltenyi Biotec) and IL-15 (5 ng/mL,
Miltenyi Biotec) in 24-well plates at 37C in a humidified 5% CO2
incubator.
In the original method (Figure 1A), the electroporated cells were
transferred to CD3/CD28 mAb (Miltenyi Biotec)-coated plates the
day following electroporation without feeder ATCs (original).
We compared two other different culture conditions. In CD3/CD28-
ATC condition, electroporated cells were co-cultured with feeder
ATCs on day 0 and then transferred to CD3/CD28mAb-coated plates
on day 1. In ACE condition, electroporated cells were stimulated
with feeder ATCs pulsed with four viral peptide pools (MACS138 Molecular Therapy: Methods & Clinical Development Vol. 8 MarchGMP PepTivator; AdV5 Hexon, CMV pp65, EBV EBNA-1, and
BZLF1) on day 0.
On day 7, 2  106 cells were transferred into G-Rex10 culture flasks
(Wilson Wolf Manufacturing, New Brighton, MN, USA) with 30 mL
of IL-7 (10 ng/mL)/IL-15 (5 ng/mL)-containing TexMACS with
2  106 of ACE-pulsed irradiated ATCs for the ACE CAR-T and
with 2 106 of unpulsed irradiated ATCs for CD3/CD28-ATC condi-
tion, or without stimulation for original condition. On day 14, CAR-T
cells cultured under all conditions were collected and analyzed.
Preparing Feeder ATCs
For preparing feeder ATCs, PBMCs were stimulated on CD3/
CD28mAb-coated plates for 3 days then transferred to regular plates
and maintained for 6–8 days supplemented with IL-7 (10 ng/mL)/
IL-15 (5 ng/mL). The cells were then harvested and cryopreserved
on days 9–11 after initial stimulation. ATCs were thawed 2–3 days
before use and re-stimulated on CD3/CD28mAbs-coated plates for
2–3 days then irradiated at 30 Gy just before being added to the
culture, as previously reported.16
Flow Cytometry
With the use of the BD FACSCalibur with BD Cell-Quest Pro soft-
ware (BD Biosciences, Franklin Lakes, NJ, USA), the surface markers
of the expanded CAR-T cells were analyzed using allophycocyanin
(APC)-conjugated CD3 mAbs, phycoerythrin (PE)-conjugated CD4
mAbs, APC-conjugated CD8 mAbs, APC-conjugated CD45RA
mAbs, PE-conjugated CD56 mAbs, PE-conjugated CD62L mAbs,
and PE-conjugated CCR7 mAbs (all mAbs were purchased fromMil-
tenyi Biotec). T cell expression of CAR was examined using a specific
anti-idiotype single-chain variable fragment (scFV) mAbs, which was
kindly provided by Dr. Lawrence Cooper (MD Anderson Cancer
Center).26 The data were analyzed using FlowJo software (TreeStar;
http://www.flowjo.com/).
ELISpot Assay
We performed the ELISpot assay to examine viral antigen-specific
IFN-g production by either ACE CAR-T or ACE NT-T cells using
the human IFN-g ELISpot PLUS kit (Mabtech, Nacka Strand,
Sweden) according to the manufacturer’s instructions. In brief, we
cultured ACE CAR-T or NT-T cells (5  104 cells/well) in the pres-
ence of pp65, hexon, EBNA1, BZLF1, or medium alone (control).
After 20 hr of incubation, the spots were counted by an automated
ELISpot reader (Autoimmun Diagnostika, Strassberg, Germany).
Intracellular Cytokine Assay
We performed intracellular cytokine staining to determine whether
the CAR+ population could respond to viral antigens. In brief, ACE
CAR-T cells were stimulated with pp65, hexon, EBNA1, BZLF1, or
medium alone (control). After 4 hr of incubation, cells were harvested
and stained with the anti-idiotype scFV mAbs described earlier.
Then, the cells were fixed and permeabilized according to the manu-
facturer’s instruction. Finally, the cells were stained with IFN-g and
analyzed by flow cytometry.2018
www.moleculartherapy.orgAnnexin V Apoptosis Assay
Electroporated cells were stimulated with either viral peptides (ACE)
or CD3/CD28 mAbs (CD3/CD28-ATC) in the presence of autolo-
gous ATCs. Seven days after stimulation, the cells were harvested,
stained with Annexin V (IMMUNOCYTO Cytotoxicity Detection
Kit; MBL International Corporation, Woburn, MA, USA), APC-con-
jugated CD3, and Alexa Fluor 488-conjugated specific anti-idiotype
scFV mAbs, and analyzed via flow cytometry.Co-culture Experiments
To examine the anti-leukemic activity of CAR-T cells, ACE
CD19.CAR-T cells, CD3/CD28-ATC CD19.CAR-T cells, and the
original CD19.CAR-T cells were added to 5  105 CD19+ leukemic
cells (SU/SR) at E:T ratios of 1:5, 1:50, and 1:100 into the wells of a
48-well culture plate containing RPMI 1640 medium plus 10% fetal
bovine serum without cytokines and cultured for 5 days. At the
indicated points, the number of viable cells was determined using
a trypan blue exclusion test, and the percentage of T cells and
CD19+ cells were determined by flow cytometry using APC-conju-
gated CD3 mAbs and PE-conjugated CD19 mAbs. IFN-g levels
in culture media were measured by ELISA assay (R&D Systems,
Minneapolis, MN)In Vivo Experiments
NSG mice were originally generated by Jackson Laboratory (Bar
Harbor, ME, USA) and purchased from Charles River Laboratories
Japan (Yokohama, Japan). All mouse experiments were performed
in accordance with the Animal Husbandry and Institutional Animal
Care and Use Committee guidelines of the Nagoya University Grad-
uate School of Medicine.
NSGmice received intravenous injections of 1 106 luciferase-trans-
duced Daudi cells. Three days later, they were intravenously infused
with 1  107 CD19.CAR-T cells. The cell counts of the infused cells
were based on the total cell number. Untreated animals served as
controls.
Biodistribution of Daudi cells was assessed twice weekly using the
In Vivo Imaging System (Xenogen Corporation, Alameda, CA,
USA) as described previously.27,28 Mice were euthanized at prede-
fined endpoints or when euthanasia criteria were met in accordance
with the Center for Comparative Medicine at the Nagoya University
Graduate School of Medicine.Statistical Analysis
The results from three culture experiments were expressed as the
means ± SD. An unpaired t test was used to identify any significant
differences among the three independent groups. Statistical signifi-
cance was defined as p < 0.05.SUPPLEMENTAL INFORMATION
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